All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Dividend yields can be like ladders: The higher you go, the scarier it gets. Many investors are more leery of ultra-high ...

Canoo said on Friday night that it has filed for Chapter 7 bankruptcy and “will cease operations effective immediately,” ...